EcoDrugPlus

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSLCRG00005018648
Gene Symbol: MAPK8A
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSLCRG00005007318
Gene Symbol: MAPK8B
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSLCRG00005012859
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSLCRG00005009481
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSLCRG00005020546
Gene Symbol: MAP2K2A
3 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSLCRG00005002947
Gene Symbol: MAP2K2B
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSLCRG00005003626
Gene Symbol: MAP3K10
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSLCRG00005015370
Gene Symbol: MAP3K11
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLCRG00005014710
Gene Symbol: MAP3K12
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLCRG00005016991
Gene Symbol: MAP3K12
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSLCRG00005006646
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSLCRG00005021692
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).